Alector, Inc.（ALEC）の株式分析ALECAlector, Inc.

Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Alector Inc is currently trading at $2.34, with a forward P/E ratio of 8.47, indicating potential undervaluation compared to future earnings. However, the recent termination of its collaboration with GSK has caused significant uncertainty, leading to a 13% drop in shares. The main risk is the company's ongoing negative net income, which was -22,990,000 USD in Q2 2026, reflecting challenges in achieving profitability. Given these factors, it may be prudent to hold rather than buy at this time.